Seeking Alpha

Seattle Genetics (SGEN -3.1%) expands a partnership with Abbott (ABT -1.1%) in which the latter...

Seattle Genetics (SGEN -3.1%) expands a partnership with Abbott (ABT -1.1%) in which the latter will pay Seattle an upfront fee of $25M to use its antibody-drug conjugate to help develop treatments for cancer. Seattle will also receive maintenance fees and research support payments, up to $220M in milestones, and royalties (PR.)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs